Yearly zoledronic acid in postmenopausal osteoporosis - Reply

被引：0
|
作者：
Black, Dennis [1 ]
Eriksen, Erik
Sellmeyer, Deborah
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94107 USA
[2] Novartis Pharma, CH-4002 Basel, Switzerland
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 357卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：714 / 715
页数：2
相关论文
共 50 条
  • [31] Zoledronic acid safety and efficacy over 5 years in postmenopausal osteoporosis
    Devogelaer, J. P.
    Burckhardt, P.
    Meunier, P.
    Kaufman, J. M.
    Lippuner, K.
    Body, J. J.
    Samsioe, G.
    Felsenberg, D.
    Brown, J.
    Garnero, P.
    Sanna, L.
    Ortmann, C. E.
    Krasnow, J.
    Eriksen, E.
    Fashola, T. F.
    Trechsel, U.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S213 - S213
  • [32] A Clinician's Perspective on the Use of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis
    Lewiecki, E. Michael
    JOURNAL OF CLINICAL DENSITOMETRY, 2008, 11 (04) : 478 - 484
  • [33] Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis
    Devogelaer, J. P.
    Brown, J. P.
    Burckhardt, P.
    Meunier, P. J.
    Goemaere, S.
    Lippuner, K.
    Body, J. J.
    Samsioe, G.
    Felsenberg, D.
    Fashola, T.
    Sanna, L.
    Ortmann, C. E.
    Trechsel, U.
    Krasnow, J.
    Eriksen, E. F.
    Garnero, P.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 (09) : 1211 - 1218
  • [34] Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: results from HORIZON-PFT
    Miller, P.
    Sellmeyer, D.
    Boonen, S.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S129 - S130
  • [35] Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: Results from horizon-PFT
    Miller, P.
    Delmas, R.
    Sellmeyer, D.
    Abrams, K.
    Hu, H.
    Lippuner, K.
    Boonen, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 523 - 524
  • [36] Effect of Once-Yearly Zoledronic Acid 5 mg Infusion on Fracture Incidence in Postmenopausal Osteoporosis: Subgroup Analysis of the Horizon PFT Study
    Eastell, R.
    Black, D. M.
    Boonen, S.
    Cummings, S. R.
    Delmas, P. D.
    Palermo, L.
    Mesenbrink, P.
    Cauley, J. A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S9 - S9
  • [37] Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: Results from horizon-PFT
    Miller, Paul
    Sellmeyer, Deborah
    Boonen, Steven R.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S227 - S228
  • [38] Postmenopausic osteoporosis treatment with yearly doses of intravenous Zoledronic acid. A Venezuelan Observational Study
    Nieto, E. J.
    Salinas, J. R.
    Torres, R. A.
    BONE, 2011, 48 : S218 - S219
  • [39] CLINICAL ASSESSMENT AND EFFICACY OF ONCE-YEARLY INTRAVENOUS ZOLEDRONIC ACID IN KOREAN OSTEOPOROSIS PATIENTS
    Park, Y. -S.
    Lee, J. -H.
    Kim, H. -S.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S66 - S66
  • [40] Zoledronic Acid Acutely Increases Sclerostin Serum Levels in Women With Postmenopausal Osteoporosis
    Catalano, Antonino
    Morabito, Nancy
    Basile, Giorgio
    Brancatelli, Santa
    Cucinotta, Domenico
    Lasco, Antonino
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (05): : 1911 - 1915
12345